HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistry.

Saved in:
Bibliographic Details
Title: HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistry.
Authors: Wilcock D; ARUP Laboratories, Salt Lake City, Utah, US., Sirohi D; Department of Pathology, University of California-San Francisco, San Francisco, California, US., Coleman JF; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Adelhardt P; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Kim JT; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Albertson D; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Affolter K; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Beech C; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Jedrzkiewicz J; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Ruano AL; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Cleary AS; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Mahlow J; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Balatico M; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US., Gulbahce HE; ARUP Laboratories, Salt Lake City, Utah, US.; Department of Pathology and Laboratory Medicine, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, US.
Source: American journal of clinical pathology [Am J Clin Pathol] 2025 Jun 03; Vol. 163 (6), pp. 837-846.
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 0370470 Publication Model: Print Cited Medium: Internet ISSN: 1943-7722 (Electronic) Linking ISSN: 00029173 NLM ISO Abbreviation: Am J Clin Pathol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1943-7722
DOI:10.1093/ajcp/aqaf006